From rapid screening to comprehensive due diligence. Physician and BME-led analysis powered by real-time federal data and a proprietary multi-domain framework.
Service Tiers
Clear visibility into what you get at every price point
| Feature |
$2,500
Quick Score
|
$7,500
Founder Score
|
$15,000
Investor Score
|
$25,000
Corporate Score
|
|---|---|---|---|---|
| 25-Category Scoring | ✓ | ✓ | ✓ | ✓ |
| Federal & Clinical Data | ✓ | ✓ | ✓ | ✓ |
| Confidence Bands | ✓ | ✓ | ✓ | ✓ |
| Executive PDF Report | ✓ | ✓ | ✓ | ✓ |
| Data Audit Trail | ✓ | ✓ | ✓ | ✓ |
| Per-Category Narratives | — | ✓ | ✓ | ✓ |
| Actionable Recommendations | — | ✓ | ✓ | ✓ |
| Interactive HTML Dashboard | — | ✓ | ✓ | ✓ |
| MD Debrief (30 min) | — | ✓ | ✓ | — |
| Competitive Benchmarking (2000+ devices) | — | — | ✓ | ✓ |
| IC-Ready Analysis | — | — | ✓ | ✓ |
| Market Sizing / TAM | — | — | ✓ | ✓ |
| M&A Integration Risk | — | — | — | ✓ |
| Manufacturing Scale-Up | — | — | — | ✓ |
| Board-Ready Deck | — | — | — | ✓ |
| Strategy Session (60 min) | — | — | — | ✓ |
| Turnaround | 24 hrs | 48 hrs | 48 hrs | 48 hrs |
The Process
Three simple steps from submission to insight
15-field intake form. Tell us about your device, company, and strategy. Regulatory approach, clinical evidence, market positioning, IP landscape. Takes 10 minutes.
Automated federal data cross-reference plus analyst review (Founder tier and up). Proprietary multi-domain scoring engine. All data sources cited in your report.
Brief delivered with composite score, category breakdown, strengths, risks, and next steps. Upgrade available at any time. Optional analyst debrief included.
Based on comprehensive multi-category analysis across multiple proprietary assessment domains
Multi-Source
Every score is backed by verified federal databases, peer-reviewed research, and proprietary data sources across multiple domains
Real-time monitoring of FDA submissions, approvals, adverse events, and recalls across all product classifications.
Comprehensive synthesis of clinical trial data, peer-reviewed literature, and real-world evidence.
Patent landscape analysis, freedom-to-operate assessment, and competitive IP positioning.
Payer coverage analysis, coding pathways, and commercial viability assessment.
Funding history, financial health indicators, and comparable transaction analysis.
Semantic Scholar, NIH publications, competitive analysis
Physician and BME-led, engineering-validated due diligence. 40–70+ page deliverables with physician and BME review. Every engagement is staffed by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Regulatory readiness, clinical evidence strategy, competitive landscape, fundraising positioning, and go-to-market planning.
$20,000Technology readiness, patent landscape, commercialization pathway, licensing strategy, and institutional IP protection.
$15,000Portfolio company screening, stage-specific guidance, investor readiness, and program outcome acceleration.
$15,000Investment-grade analysis: risk scoring, regulatory pathway, clinical evidence, IP landscape, market access, team evaluation.
$75,000Operational due diligence for portfolio companies: platform capability analysis, synergy identification, deal structure support, post-acquisition roadmap.
from $175,000Full strategic assessment for corporate M&A: integration risk, competitive impact, regulatory environment, manufacturing readiness, IP licensing.
$150,000Ongoing Intelligence
Continuous monitoring of regulatory, clinical, and competitive developments — available as an add-on to any assessment tier.
Volume Programs
For organizations assessing multiple products, targets, or portfolio companies, Vantage offers volume programs with dedicated support.
Verticals
The same data-driven methodology, purpose-built for your life science vertical. Each vertical is calibrated with domain-specific risk factors and benchmarks.
Why Choose Vantage
Vantage fills the gap between traditional consulting, DIY analysis, and generic data platforms
We give you the clinical rigor of deep consulting, the speed of automated data platforms, and the independence that neither can offer. That's why founders, investors, and corporate teams choose us when the decision matters.
Founded by Arvind Ravinutala, MD and Aswini Ravinutala, BME. Vantage combines physician and BME-led clinical insight with biomedical engineering rigor, powered by multi-source federal and clinical intelligence and proprietary automated analysis.
By Segment
Different tiers for different use cases across the biomedical ecosystem
Choose your intelligence level. Start with a Quick Score for rapid triage, or schedule comprehensive due diligence with our founding team. Upgrade at any time.